BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28655925)

  • 1. Natural history of t(11;14) multiple myeloma.
    Lakshman A; Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Leukemia; 2018 Jan; 32(1):131-138. PubMed ID: 28655925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple myeloma with de novo del(17p).
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.
    Sagaster V; Kaufmann H; Odelga V; Ackermann J; Gisslinger H; Rabitsch W; Zojer N; Ludwig H; Nösslinger T; Zielinski C; Drach J
    Eur J Haematol; 2007 Mar; 78(3):227-34. PubMed ID: 17253972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.
    Lange K; Gadzicki D; Schlegelberger B; Göhring G
    Leuk Res; 2010 Aug; 34(8):1002-6. PubMed ID: 20022374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
    Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
    Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
    Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
    Byun JM; Kim D; Shin DY; Kim I; Koh Y; Yoon SS
    In Vivo; 2019; 33(2):611-619. PubMed ID: 30804149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
    J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
    Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
    Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T; Bringhen S; Gay F; Attal M; Passera R; Spencer A; Offidani M; Kumar S; Musto P; Lonial S; Petrucci MT; Orlowski RZ; Zamagni E; Morgan G; Dimopoulos MA; Durie BG; Anderson KC; Sonneveld P; San Miguel J; Cavo M; Rajkumar SV; Moreau P
    J Clin Oncol; 2015 Sep; 33(26):2863-9. PubMed ID: 26240224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of acquired del(17p) in multiple myeloma.
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Adv; 2019 Jul; 3(13):1930-1938. PubMed ID: 31248884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
    Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
    Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
    Soekojo CY; Wang GM; Chen Y; Casan J; Wolyncewicz G; Lin A; Poon LM; de Mel S; Koh LP; Tan LK; Ooi MG; Nagarajan C; Liu Y; Lai YY; Huang XJ; Spencer A; Gopalakrishnan SK; Lu J; Chng WJ
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e470-e477. PubMed ID: 31171473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.
    Chen L; Fan F; Deng J; Xu J; Xu A; Sun C; Hu Y
    Ann Hematol; 2019 Apr; 98(4):963-970. PubMed ID: 30610280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
    Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
    Avet-Loiseau H; Durie BG; Cavo M; Attal M; Gutierrez N; Haessler J; Goldschmidt H; Hajek R; Lee JH; Sezer O; Barlogie B; Crowley J; Fonseca R; Testoni N; Ross F; Rajkumar SV; Sonneveld P; Lahuerta J; Moreau P; Morgan G;
    Leukemia; 2013 Mar; 27(3):711-7. PubMed ID: 23032723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
    El-Ghammaz AM; Abdelwahed E
    Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.